EMA Authorised: Columvi (Glofitamab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Columvi (glofitamab) from Roche Registration GmbH for diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse. MAH: Roche Registration GmbH. Decision date: 24/07/2025